1 Cannabis-associated symptom profiles in patients with first episode 2 psychosis and population controls

3

4 *Diego Quattrone, MD^{1,2,†}; Laura Ferraro, PhD³; Giada Tripoli, MsC⁴; Erika La*
5 *Cascia, PhD³; Harriet Quigley, MD⁴; EU-GEI group^{*}; Charlotte Gayer-Anderson,*
6 *PhD⁵; Peter B. Jones, MD, PhD^{6,7}; James B. Kirkbride, PhD⁸, Daniele La Barbera,*
7 *MD³; Ilaria Tarricone, MD, PhD⁹; Michael T. Lynskey, PhD¹⁰; Tom P. Freeman,*
8 *PhD^{10,11}; Pak C. Sham, MD, PhD^{12,13}; Alaistar Cardno, PhD¹⁴; Evangelos Vassos,*
9 *MD, PhD¹; Jim van Os^{15,16}; Craig Morgan⁵; Ulrich Reininghaus, PhD^{5,16,17}; Cathryn*
10 *M. Lewis¹; Robin M. Murray, MD, FRS^{2,4} and Marta Di Forti, MD, PhD^{1,2}*

11

12 ¹ Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry,
13 Psychology and Neuroscience, King's College London, London, United Kingdom, SE5
14 8AF

15 ² National Institute for Health Research (NIHR) Maudsley Biomedical Research
16 Centre, South London and Maudsley NHS Foundation Trust, King's College London,
17 London, UK

18 ³ Department of Experimental Biomedicine and Clinical Neuroscience, University of
19 Palermo, Via G. La Loggia 1, 90129 Palermo, Italy

20 ⁴ Department of Psychosis Studies, Institute of Psychiatry, Psychology and
21 Neuroscience, King's College London, De Crespigny Park, Denmark Hill, London,
22 United Kingdom SE5 8AF

23 ⁵ Department of Health Service and Population Research, Institute of Psychiatry,
24 Psychology and Neuroscience, King's College London, De Crespigny Park, Denmark
25 Hill, London, United Kingdom, SE5 8AF

26 ⁶ Department of Psychiatry, University of Cambridge, Herchel Smith Building for
27 Brain & Mind Sciences, Forvie Site, Robinson Way, Cambridge, CB2 0SZ, United
28 Kingdom

29 ⁷ CAMEO Early Intervention Service, Cambridgeshire & Peterborough NHS
30 Foundation Trust, Cambridge, CB21 5EF, UK

31 ⁸ Psylife Group, Division of Psychiatry, University College London, 6th Floor, Maple
32 House, 149 Tottenham Court Road, London, W1T 7NF

33 ⁹ Department of Medical and Surgical Science, Psychiatry Unit, Alma Mater
34 Studiorum Università di Bologna, Viale Pepoli 5, 40126 Bologna, Italy

35 ¹⁰ National Addiction Centre, Institute of Psychiatry, Psychology & Neuroscience,
 36 King's College London, 4 Windsor Walk, London, SE5 8BB, UK
 37 ¹¹ Department of Psychology, University of Bath, 10 West, Bath, BA2 7AY, UK
 38 ¹² Department of Psychiatry, the University of Hong Kong, Hong Kong, China;
 39 ¹³ Centre for Genomic Sciences, Li KaShing Faculty of Medicine, The University of
 40 Hong Kong, Hong Kong, China
 41 ¹⁴ Academic Unit of Psychiatry and Behavioural Sciences, University of Leeds, Leeds,
 42 United Kingdom
 43 ¹⁵ Brain Centre Rudolf Magnus, Utrecht University Medical Centre, Utrecht, The
 44 Netherlands
 45 ¹⁶ Department of Psychiatry and Neuropsychology, School for Mental Health and
 46 Neuroscience, South Limburg Mental Health Research and Teaching Network,
 47 Maastricht University Medical Centre, P.O. Box 616, 6200 MD Maastricht, The
 48 Netherlands
 49 ¹⁷ Central Institute of Mental Health, Medical Faculty Mannheim, University of
 50 Heidelberg, Mannheim, Germany

51

52 **Word count:**

53

54 **Abstract: 244 words**

55 **Main text: 3,335 words**

56

57 †Correspondence to: Dr Diego Quattrone, diego.quattrone@kcl.ac.uk, Social, Genetic
 58 and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and
 59 Neuroscience, King's College London, London, United Kingdom, SE5 8AF

60 ‡For a full list of the EU-GEI group authors, see Acknowledgments

61

62

63

64 **Abstract**

65 **Objective:** The evidence is mixed on whether cannabis use is associated with a
 66 particular symptomatology in first episode psychosis (FEP) patients.

67 The authors set out to investigate a) patterns of association between cannabis use
 68 and transdiagnostic symptom dimensions; b) whether the extent of use of cannabis
 69 contributes to the variation in clinical and subclinical symptom profiles.

70 **Method:** The authors analysed data from 901 patients and 1235 controls recruited
 71 across six countries, as part of the European Network of National Schizophrenia

72 Networks Studying Gene-Environment Interactions (EU-GEI) study. Item response
73 modelling was used to estimate two bifactor models, which included general and
74 specific dimensions of psychotic symptoms in patients and psychotic experiences in
75 controls. The associations between these dimensions and cannabis use was evaluated
76 using linear mixed effects models analyses.

77 **Results:** In patients, there was a linear relationship between the positive symptom
78 dimension and the extent of lifetime exposure to cannabis, with daily users of high
79 potency cannabis having the highest score ($B=0.35$; 95%CI 0.14 to 0.56). Moreover,
80 negative symptoms were more common among patients who never used cannabis
81 compared with those with any pattern of use ($B=-0.27$; 95%CI -0.42 to -0.12).

82 In controls, psychotic experiences were associated with current use of cannabis but
83 not with the extent of lifetime use.

84 Neither patients nor controls presented differences in the depressive dimension
85 related to cannabis use.

86 **Conclusions:** The extent of use of cannabis explains part of the heterogeneous
87 distribution of positive and negative symptoms of FEP patients.

88

89

90

91 **Introduction**

92 There is compelling evidence to suggest an association between cannabis use and
93 psychotic disorders, with highest risk among those using high potency cannabis on a
94 daily basis (1). However, how cannabis use affects the symptoms psychotic patients
95 present with remains unclear.

96 The existence of psychotic symptomatology particularly associated with cannabis use
97 has been historically described in several case series (2-5). Nevertheless, case and
98 cohort studies have found mixed results as to whether (6-11) or not (12-15) psychotic
99 patients using cannabis present with more positive symptoms than those not using
100 cannabis. Moreover, there is limited and mixed evidence of any relationship between
101 cannabis use and negative symptoms in psychosis. Some reports suggest fewer
102 negative symptoms in psychotic patients that use of cannabis (16, 17), which is
103 consistent with having enough social skills to obtain the substance. However, this
104 association has not been confirmed in other studies (7, 8) and others even reported a
105 positive association (9).

These inconsistencies might be explained by differences in study design and methods. For example, only a few findings were based on first episode psychosis (FEP) patients (7, 8, 10), which allows one to reduce selection and recall bias, set a common time point and minimise the confounding effect of antipsychotic drugs on symptoms. In addition, a metanalysis of longitudinal studies concluded that most results lacked sufficient power to detect an effect of cannabis on symptoms, or inadequately controlled for potential confounders (18). Furthermore, although a few studies have information on frequency of use, all failed to obtain detailed information on the lifetime pattern of cannabis use, especially on the type and strength of cannabis used. Of note, potent cannabis varieties, with high concentrations of Delta-9-Tetrahydrocannabinol (Δ 9-THC), have been associated with the most harm to mental health (19, 20) and, in recent years, they have become more available worldwide (21, 22). Finally, although the use of a symptom-based approach would be an essential requirement for understanding to what extent environmental factors influence the clinical heterogeneity of psychosis (23), no studies have investigated how cannabis use is related to different psychotic symptom dimensions.

On the other hand, in the general population there are consistent findings regarding the association between cannabis use and subthreshold psychotic symptoms (24). However, most studies presented bias in the selection of non-psychotic population, and all had limited geographical coverage (24).

In this study, we set out to clarify the association between detailed patterns of cannabis use and transdiagnostic symptom dimensions in a large multinational FEP sample.

In addition, we examine the association between detailed patterns of cannabis use and subclinical symptom dimensions in a large sample of controls, that are representative of the population at risk in each catchment area.

Specifically, we sought to test the hypotheses that: (1) positive psychotic symptoms are more common among FEP patients with more frequent lifetime use of cannabis and greater exposure to use of high potency varieties; (2) positive psychotic experiences are more common in population controls with a recent use of cannabis; (3) negative symptoms are more common among those patients who have never used cannabis.

Methods

Study design and participants

This analysis is based on data from the incidence and case-control study work package of the EUropean network of national schizophrenia networks studying Gene-Environment Interactions (EU-GEI).

FEP individuals were identified between 2010 and 2015 across six countries to examine incidence rates of schizophrenia and other psychotic disorders (25), and symptomatology at psychosis onset (23). For examining risk factors, we sought to perform an extensive assessment on approximately 1,000 FEP patients and 1,000 population-based controls during the same time period.

Patients were included in the case-control study if they met the following criteria during the recruitment period: (a) aged between 18 and 64 years; (b) presentation with a clinical diagnosis for an untreated FEP, even if longstanding [International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) codes F20-F33]; (c) resident within the catchment area. Exclusion criteria were: (a) previous contact with psychiatric services for psychosis; (b) psychotic symptoms with any evidence of organic causation; and (c) transient psychotic symptoms resulting from acute intoxication (ICD-10: F1x.5).

The recruitment of controls followed a mixture of random and quota sampling methods, in order to achieve the best possible representativeness in age, sex, and ethnicity of the population living in each catchment area. The identification process varied by site and was based on locally available sampling frames, including mostly the use of lists of all postal addresses and general practitioners' lists from randomly selected surgeries. When these resources were not fully available, internet and newspapers advertising were used to fill quotas. Exclusion criteria for controls were: (a) diagnosis of a psychotic disorder; (b) ever having been treated for psychotic symptoms.

We analysed data from eleven catchment areas, including urban and less urban populations (i.e. Southeast London, Cambridgeshire and Peterborough (England); central Amsterdam, Gouda and Voorhout (the Netherlands); Bologna municipality, city of Palermo (Italy); Paris [Val-de-Marne], Puy-de-Dôme (France); Madrid

[Vallecas], Barcelona (Spain); and Ribeirão Preto (Brazil) (23). Further information on the case-control sample and the recruitment strategies is included in the supplementary material.

Measures

Data on age, sex, and ethnicity was collected using a modified version of the Medical Research Council Sociodemographic Schedule (26). The OPERational CRITeria (OPCRIT) system (27) was used by centrally trained investigators, whose reliability was assessed before and throughout the study ($k=0.7$), to assess psychopathology and generate research-based diagnoses based on different diagnostic classification systems. The Community Assessment of Psychic Experiences (CAPE) (28) was administered to controls to self-report their psychotic experiences. The reliability of the CAPE is good for all the languages spoken in the countries forming part of the EU-GEI study (<http://cape42.homestead.com>).

A modified version of the Cannabis Experience Questionnaire (CEQ_{EU-GEI}) (29) was used to collect extensive information on the patterns of use of cannabis and other drugs. Based on our EU-GEI paper on cannabis (30) we included six measures of cannabis use (Supplementary Table S2), along with a variable measuring specific patterns of cannabis exposure by combining the frequency of use with the potency of cannabis. As illustrated in the supplementary material, the cannabis potency variable was based on the data published in the EMCDDA 2016 (31, 32).

We selected confounders based on their possible association with cannabis use and/or symptom dimensions. These included: sex; age; ethnicity; use of stimulants, hallucinogens, ketamine, cocaine, crack, and novel psychoactive substances (current use no=0; yes=1); current use of cigarettes (no use or smoking less than 10 cigarettes per day=0; smoking 10 cigarettes or more per day=1), and current use of alcohol (drinking less than 10 units per week= 0; drinking more than 10 alcohol units per week=1).

Statistical analysis

Dimensions of psychotic symptoms in patients and psychotic experiences in controls

Data from OPCRIT and CAPE were analysed using multidimensional item response modelling in *Mplus*, version 7.4 (33), to estimate two bifactor models, based on the associations among observer ratings of psychotic symptoms in patients and self-

ratings of psychotic experiences in controls. This methodology is described in full in our EU-GEI paper on symptom dimensions in FEP patients (30), and it was likewise applied to psychotic experiences in population controls. Briefly, CAPE items were dichotomized as 0 ‘absent’ or 1 ‘present’. In order to ensure sufficient covariance coverage for item response modelling, we used items with a valid frequency of ‘present’ $\geq 10\%$ in our sample, and we excluded those items with low correlation values ($< .3$) based on the examination of the item correlation matrix. Data used in the analysis contained missing values, which we assumed to be missing at random, allowing for the maximum likelihood estimator to provide unbiased estimates. As in the previous analysis in patients, the bifactor solution was compared with other solutions (i.e., unidimensional, multidimensional, and hierarchical models) using Log-Likelihood (LL), Akaike Information Criterion (AIC), Bayesian Information Criterion (BIC), and Sample-size Adjusted BIC (SABIC) as model fit statistics. Path diagrams that illustrate these models are presented in Supplementary Figure S1. Reliability and strength indices such as McDonald’s omega (ω) (34), omega hierarchical (ω_H) (34), and index H (35), were computed to determine: 1) the proportion of common variance accounted by general and specific symptom dimensions; 2) the proportion of reliable variance accounted by the general dimension not unduly affected by the specific dimensions; 3) the proportion of reliable variance accounted for by each specific dimension not unduly affected by the general and all the other specific dimensions; 4) the overall reliability and replicability of the bifactor construct of psychosis-like experiences. Finally, we generated factor scores for one general psychotic experience dimension and three specific dimensions of positive, negative, and depressive psychotic experiences. For patients, we used the previously generated factor scores for one general psychosis dimension and five specific dimensions of positive, negative, disorganised, manic, and depressive symptoms (23).

Symptom dimensions and cannabis use

We evaluated the relationship between psychotic symptom dimensions in patients, or psychotic experience dimensions in controls, and cannabis use using linear mixed effects models in STATA 14. We specifically modelled symptom dimension scores as a function of each of the six measures of cannabis use. We then evaluated the combined effect of frequency of use and potency of cannabis. To account for the non-

independence of symptom profiles of subjects assessed within the same country (for example, due to cultural similarities), and for the potential within-site correlation (for example, due to context factors), we fitted a three-level mixed model, where the random effect encompassed a double level of random intercepts: one due to the countries, and another due to the sites within the countries.

We conducted a sensitivity analysis to estimate an additional bifactor model based on the distress elicited by the psychotic experiences. This aimed to rule out the possibility in controls that 1) positive psychotic experiences were no distressing if associated to cannabis use, and 2) self-rating of positive psychotic experiences was influenced by contextual or cultural factors. We therefore confirmed our findings further adjusting the linear mixed effects models for the distress factor scores.

Results

Sample characteristics

We analysed data from 901 FEP patients and 1,235 controls. Main Socio-demographic characteristics and history of substance misuse of patients and controls are presented in Supplementary Table S1. Supplementary Tables S3.1 and S3.2 show the sample prevalence of psychotic experiences in controls and of psychotic symptoms in patients.

Bifactor model of psychotic experiences in controls

Table 1 shows that, similar to our previous analysis of the OPCRIT items (23), the bifactor model provided the best fit for the CAPE items, as illustrated by AIC, BIC and SABIC substantially lower compared with competing models. This solution explained 60% of the unique variance. In addition, Figure 1 shows that, within the bifactor model, the explained variance was due to individual differences mostly on the general psychotic experience dimension. This is illustrated by the relative omega coefficient, which, for example, showed that 85% of the reliable variance was due to the general dimension when partitioning out the variability in scores due to the specific dimensions. Moreover, factor loadings of moderate to high magnitude were observed for most items on the general psychotic experience dimension, whereas factor loadings of a smaller magnitude were observed for the specific dimensions (Figure 1). Consistently, the index H, which is a measure of the construct reliability and replicability across studies (35), was very high for the general dimension (0.92),

moderate for positive (0.78) and negative (0.71) dimensions and lower for the depressive dimension (0.41).

Table 1. Model fit statistics of unidimensional, multidimensional, bifactor, second-order models for psychotic symptoms and psychotic experiences

CAPE (CONTROLS)				
	Full information fit statistics ^a			
	LL	AIC	BIC	SABIC
A - Unidimensional Model	-23638	47397	47715	47524
B - Multidimensional Model (five uncorrelated factors)	-23844	47808	48126	47936
C - Multidimensional Model (five correlated factors)	-23341	46808	47142	46942
D - Bifactor Model (one general factor and five specific uncorrelated factors)	-23139	46458	46935	46649
E - Hierarchical Model (five first-order specific correlated factors and one second order general factor)	-23341	46807	47135	46938
OPCRIT (PATIENTS)				
	Full information fit statistics ^a			
	LL	AIC	BIC	SABIC
A - Unidimensional Model	-29965	60126	60618	60306
B - Multidimensional Model (five uncorrelated factors)	-28070	56335	56826	56515
C - Multidimensional Model (five correlated factors)	-27894	56004	56546	56202
D - Bifactor Model (one general factor and five specific uncorrelated factors)	-27597	55489	56226	55759
E - Hierarchical Model (five first-order specific correlated factors and one second order general factor)	-27995	56197	56713	56386

LL, log-likelihood; AIC, Akaike Information Criterion; BIC, Bayesian Information Criterion; SABIC Sample-size Adjusted Bayesian Information Criterion
A difference of 10 in AIC, BIC and SABIC is considered important. Lower values indicate a statistically better model fit (best values across models are indicated in bold).

Figure 1. Bifactor model of psychotic experiences in controls

(□) Observed variables (No. of CAPE items); (○) Unobserved variables (latent factors); (→) standardized item loading estimation onto latent factors; G, general psychosis-like factor; Specific psychotic experiences factors: DEP, Depression; NEG, Negative; POS, Positive. Reliability and strength estimates: H =construct reliability index; ω = McDonald omega; ω_H =hierarchical omega; ω/ω_H = Relative omega.
Explanatory note: McDonald's ω is an estimate of the proportion of the common variance accounted by general and specific symptom dimensions.(34)
Relative omega (ω/ω_H) is the amount of reliable variance explained in the observed scores attributable to a) the general factor independently from the specific symptom dimensions, and 2) each specific symptom dimension independently from the general factor.
 H is an index of the quality of the measurement model based on the set of CAPE items for each dimension.(35) Indices can range from 0 to 1, with values closer to 1 indicating a better construct reliability and replicability across studies.

Symptom dimensions in patients by lifetime cannabis use, current cannabis use, age at first use, and money spent on cannabis

Models' results are presented in Table 2.1 which shows that:

1) There were no differences in the distribution of positive symptoms according to ever use of cannabis or early age at first use (≤ 15 years old). However, positive symptoms were more common among patients who currently used cannabis ($B=0.22$; 95%CI 0.04 to 0.4; $p=0.016$) and who spent more than 20 euros per week on cannabis ($B=0.35$; 95%CI 0.14 to 0.55; $p=0.001$).

2) Fewer negative symptoms were observed among those patients who used cannabis at least once compared with those who never tried ($B = -0.27$; 95%CI -0.42 to -0.12; $p < 0.001$). Early age at first use and current use of cannabis was not associated with negative symptomatology.

3) Manic symptoms were more frequent among patients who had either ever use ($B = 0.31$; 95%CI 0.14 to 0.47; $p < 0.001$) or current use of cannabis ($B = 0.19$; 95%CI 0.01 to 0.36; $p = 0.035$).

4) There were no differences in the distribution of the scores on the depressive and general psychosis dimensions according to any measure of cannabis use.

Table 2.1 Symptom dimensions in FEP patients by measures of cannabis use^a

Model	Ever used cannabis B (95% CI)	Current use of cannabis B (95% CI)	Age at first use of cannabis B (95% CI)	Money used for cannabis B (95% CI)
Positive symptom dimension	0.14 (-0.04 to 0.31)	0.22* (0.04 to 0.4)	0.08 (-0.11 to 0.26)	0.35** (0.14 to 0.55)
Negative symptom dimension	-0.27*** (-0.42 to -0.12)	-0.09 (-0.26 to 0.07)	0.13 (-0.03 to 0.29)	0.03 (-0.16 to 0.22)
Depressive symptom dimension	-0.08 (-0.24 to 0.08)	-0.08 (-0.25 to 0.09)	-0.11 (-0.25 to 0.02)	-0.11 (-0.29 to 0.06)
Disorganization symptom dimension	-0.04 (-0.2 to 0.13)	0.08 (-0.09 to 0.25)	0.17 (-0.01 to 0.35)	0.2* (0.01 to 0.39)
Manic symptom dimension	0.31*** (0.14 to 0.47)	0.19* (0.01 to 0.36)	-0.09 (-0.25 to 0.07)	0.07 (-0.13 to 0.26)
General psychosis factor	0.06 (-0.07 to 0.19)	0.03 (-0.1 to 0.17)	-0.01 (-0.12 to 0.15)	0.05 (-0.1 to 0.21)

^aAll models were adjusted for age, sex, ethnicity, use of any other recreational/illicit substances and tobacco. Models were random-intercept models that included two random effects to allow symptomatology to vary across countries and across sites within countries but assumed that individual-level exposure to cannabis had a fixed effect across the entire sample.

Significance: * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$

Psychotic experiences' dimensions in population controls by lifetime cannabis use, current cannabis use, age at first use, and money spent on cannabis

Models' results are presented in Table 2.2, which shows that:

- 1) There were no differences in the distribution of positive psychotic experiences according to ever use of cannabis or early age at first use (≤ 15 years old). However, positive psychotic experiences were more commonly self-reported by subjects who currently used cannabis ($B=0.19$; 95%CI 0.01 to 0.37; $p=0.037$) and who spent more than 20 euros per week on cannabis ($B=0.31$; 95%CI 0.01 to 0.6; $p=0.044$).
- 2) There were no differences in the distribution of the depressive and negative experiences in population controls according to cannabis use.
- 3) The general psychotic experience dimension was associated with current use of cannabis ($B=0.21$; 95%CI 0.04 to 0.41; $p=0.03$).

Table 2.2 Psychotic experience dimensions in controls by cannabis use^a

Model	Ever used cannabis B (95% CI)	Current use of cannabis B (95% CI)	Age at first use of cannabis B (95% CI)	Money used for cannabis B (95% CI)
Positive psychotic experience dimension	-0.03 (-0.15 to 0.09)	0.19* (0.01 to 0.37)	0.13 (-0.05 to 0.32)	0.31* (0.01 to 0.6)
Negative experience dimension	-0.05 (-0.18 to 0.08)	-0.02 (-0.21 to 0.18)	-0.06 (-0.25 to 0.13)	-0.29 (-0.61 to 0.02)
Depressive experience dimension	-0.01 (-0.13 to 0.11)	0.01 (-0.19 to 0.20)	-0.04 (-0.15 to 0.22)	-0.01 (-0.31 to 0.33)
General psychotic experience	0.1 (-0.02 to 0.22)	0.21* (0.02 to 0.41)	-0.03 (-0.22 to 0.15)	0.16 (-0.16 to 0.48)

^aAll models were adjusted for age, sex, ethnicity, use of any other recreational/illicit substances and tobacco. Models were random-intercept models that included two random effects to allow symptomatology to vary across countries and across sites within countries but assumed that individual-level exposure to cannabis had a fixed effect across the entire sample.

Significance: * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$

Symptom dimensions by lifetime pattern of cannabis use

Preliminary analysis testing independently the effects of frequency of use and potency of cannabis showed that, only in patients, positive symptoms were more common in those who used cannabis on a daily basis or exposed to high potency varieties (Supplementary Figure S2, Supplementary Table S4.1).

Testing the combined 'type-frequency' variable in patients, we found evidence of a linear relationship between the positive symptom dimension and the extent of exposure to cannabis, with daily users of high potency cannabis showing the highest

score ($B=0.35$; 95%CI 0.14 to 0.56; $p=0.001$). Therefore, we introduced a contrast operator and plot the exposure-response relationship for positive symptoms (Figure 2), by comparing the predictive margins of the adjusted mean of each group against the grand adjusted mean of all groups. Figure 2 shows that the adjusted mean for daily users of high potency cannabis was 0.15 units greater than the grand adjusted mean. Moreover, the adjusted means for the groups who never or rarely used cannabis were respectively 0.13 or 0.14 units lower than the grand adjusted mean. A negative relationship between the negative symptom dimension score and patterns of cannabis use was also observed in patients. Figure 3 shows that patients with psychosis who never used cannabis had more negative symptoms either compared with the grand adjusted mean or with any pattern of cannabis use.

Figure 2. Positive symptom dimension in FEP patients by patterns of cannabis use.

Figure 2 shows the contrasts of the positive symptom dimension predicted mean of each group against the predicted grand mean of all groups. Values were adjusted for age, sex, ethnicity, current use of other recreational and illicit substances (such as stimulants, hallucinogens, cocaine, crack, novel psychoactive substances) and tobacco. The model was a random intercept model which allowed symptoms to vary across countries and sites within countries but assumed frequency of use and type of cannabis had an individual fixed effect. The positive value for the contrast of the daily use of high potency cannabis indicates more positive symptomatology in this group. On the other hand, negative values for the contrasts of the first two groups indicates less positive symptomatology when there is

less exposure to cannabis. These differences are statistically significant, as indicated by 95% confidence intervals that do not overlap with zero.

Figure 3. Negative symptom dimension by patterns of cannabis use.

Figure 3 shows the contrasts of the negative symptom dimension predicted mean of each group against the grand adjusted predicted mean (represented by the red line). Subjects who had never used cannabis presented with more negative symptoms compared to the whole sample. Values are adjusted for age, sex, ethnicity, current use of other recreational and illicit substances and tobacco. The model was a random intercept model which allowed symptoms to vary across countries and sites within countries, but it assumed that frequency of use and type of cannabis had an individual fixed effect.

Discussion

Principal findings

This is the first multinational study exploring the dose effect of cannabis use on dimensions of symptom in FEP patients, and on dimensions of psychotic experiences in population controls. Our findings indicate that: 1) in patients, a positive

correlation exists between the extent of premorbid cannabis use and the score at the positive symptom dimension, with daily users of high potency cannabis showing the worst symptomatology at FEP; 2) psychotic experiences in non-clinical populations is associated with current use of cannabis but is independent of the extent of lifetime exposure to cannabis; 3) negative symptoms at FEP are more common in patients who have never tried cannabis; 4) depressive symptoms are independent of any pattern of use of cannabis.

Limitations

Our findings must be considered in the context of three main limitations. First, individual data on patterns of cannabis use are not validated with biological samples. However, such methods would not allow one to ascertain the extent of cannabis use over the years (36). Moreover, studies combining self-report and laboratory data support the reliability of subjects in reporting the type of cannabis they use (37, 38). Second, we did not take into account the cannabidiol (CBD) contribution to the potency variable, as official data on its content in the different cannabis varieties were not available in most study sites. Indeed, CBD might counterbalance Δ^9 -THC effects and minimise both psychotic experiences (39) and positive psychotic symptoms (40). Third, it could be argued that self-report checklists for subclinical symptoms, such as the CAPE, might yield false positive rates, as the interpretation and rating of the experiences might be subject to contextual or cultural factors in individuals without a psychiatric history (41). However, our findings are confirmed even after adjusting the analyses for the distress elicited by psychotic experiences, which is less subject to misinterpretation (42).

Comparison with previous research

We extend previous research on cannabis and psychotic symptoms to a multinational sample confirming the association between cannabis use and positive symptoms of FEP (8, 9). Our results are in line with Schoeler et al. (2016), who carefully scrutinised the literature on the effect of continuation of cannabis use after FEP, concluding that this would be associated with a more severe positive symptomatology (43). That said, any comparison with previous research is limited by the lack of information on frequency and potency in all the previous studies along with subjects' exposure to more potent varieties of cannabis over recent years (22).

In this respect, we firstly provide some evidence that cannabis affects positive symptoms in a dose response manner, further supporting the converging epidemiological and experimental evidence that the use of cannabis with high content of Δ^9 -THC has a more detrimental effect than other varieties (20, 29, 44).

We also report evidence in a multinational FEP sample of an association between lifetime cannabis use and fewer negative symptoms, the latter often considered as a marker of greater neurodevelopmental impairment in psychotic subjects. Indeed, our findings are consistent with the hypothesis that psychotic disorders could differ in their degree of neurodevelopmental impairment, thus being characterized, for example, by less neurodevelopmental features when associated with cannabis use (45). Support for this hypothesis is provided by evidence that additional markers suggestive of neurodevelopmental impairment in psychotic disorders tend to be uncommon in cannabis-associated psychosis (45).

On the other hand, some authors have suggested that people with a psychotic disorder might use cannabis as an attempt to self-medicate negative symptoms, thus the observed reduction in negative symptomatology would be an epiphenomenon due to the cannabis intake itself (16). In principle, this possibility is unlikely since a prominent negative symptom is reduction of social and instrumental skills, which are necessary to obtain cannabis and sustain its use over time. Further, our analysis indicates a lack of a dose-response relationship between cannabis use and the negative symptom dimension score, suggesting that the difference holds between those who never tried cannabis and those who may have used it only once. Finally, it could be argued that psychotic people use cannabis to self-medicate depressive symptoms, as opposed to negative symptoms. Again, this explanation is not supported by our study, which differentiates negative and depressive dimensions to disprove the relationship between depressive symptomatology and cannabis use.

Last, we report that the cumulative exposure to cannabis does not impact on psychotic experiences in controls. One could of course argue that the largest proportion of subjects with the harmful pattern of cannabis use were patients. However, further research is needed to look into plausible mechanisms of resilience to the psychotogenic effect of cannabis as observed in our controls, who report psychotic experiences if current users but do not seem to accumulate a risk over life time cannabis use and develop psychotic disorders. Indeed, future studies should

aim to investigate if and how genetic factors, plausibly regulating the dopamine system, interact with cannabis use in shaping the quality of symptomatology.

Implications

In this multinational study, we show that the pattern of use of cannabis explains part of the heterogeneity in positive and negative symptom dimensions at first episode psychosis. Further research should aim to determine biological mechanisms underlying how cannabis impacts on different clinical manifestations of psychosis. Meanwhile, translating current findings into clinical practice, symptom dimensions are useful to stratify patients and develop and implement secondary and tertiary prevention schemes for cannabis-associated psychosis. Treatment plans should integrate harm reduction and cannabis use cessation strategies, combined with possibly better tailored treatment strategies such as the adjunct to conventional pharmacological treatment of cannabidiol (40).

Acknowledgment

The authors have no conflicts of interest to declare in relation to the work presented in this paper.

The EU-GEI Project is funded by the European Community's Seventh Framework Programme under grant agreement No. HEALTH-F2-2010-241909 (Project EU-GEI). The Brazilian study was funded by the São Paulo Research Foundation under grant number 2012/0417-0. The work was further supported by: Clinician Scientist Medical Research Council fellowship (project reference MR/M008436/1) to MDF; Veni grant from the Netherlands Organisation for Scientific Research (grant no. 451-13-022) to UR. Funders were not involved in design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review or approval of the manuscript, and decision to submit the manuscript for publication.

This paper represents independent research part-funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

***EU-GEI authors**

Hannah E Jongsma; Domenico Berardi; Lieuwe de Haan; Eva Velthorst; Michael C O'Donovan; Alexander L Richards; Andrei Szöke; Celso Arango; Antonio Lasalvia; Andrea Tortelli; Pierre-Michel Llorca; Julio Bobes; Miguel Bernardo; Julio Sanjuán; Jose Luis Santos; Manuel Arrojo; Cristina Marta Del-Ben; Paulo Rossi Menezes; Jean-Paul Selten; Kathryn Hubbard¹, Stephanie Beards¹, Simona A. Stilo², Mara Parellada³, Pedro Cuadrado⁴, José Juan Rodríguez Solano⁵, Angel Carracedo⁶, Enrique García Bernardo⁷, Laura Roldán³, Gonzalo López³, Bibiana Cabrera⁸, Esther Lorente-Rovira⁹, Paz Garcia-Portilla¹⁰, Javier Costas⁶, Estela Jiménez-López¹¹, Mario Matteis³, Marta Rapado³, Emiliano González³, Covadonga Martínez³, Emilio Sánchez⁷, Ma Soledad Olmeda⁷, Nathalie Franke¹², Fabian Termorshuizen^{13,14}, Daniella van Dam¹², Elsje van der Ven^{13,14}, Elles Messchaart¹⁴, Marion Leboyer^{15,16,17,18}, Franck Schurhoff^{15,16,17,18}, Stéphane Jamain^{16,17,18}, Grégoire Baudin^{15,16}, Aziz Ferchiou^{15,16}, Baptiste Pignon^{15,16,18}, Jean-Romain Richard^{16,18}, Thomas Charpeaud^{18,19,21}, Anne-Marie Tronche^{18,19,21}, Flora Frijda²², Daniele La Barbera^{22,23}, Giovanna Marrazzo²³, Lucia Sideli²², Crocettarachele Sartorio^{22,23}, Fabio Seminerio²², Camila Marcelino Loureiro^{24,25}, Rosana Shuhama^{24,25}, Mirella Ruggeri²⁶, Sarah Tosato²⁶, Chiara Bonetto²⁶, Doriana Cristofalo²⁶

EU-GEI group authorship affiliations

¹ Department of Health Service and Population Research, Institute of Psychiatry, King's College London, De Crespigny Park, Denmark Hill, London, United Kingdom, SE5 8AF

² Department of Psychosis Studies, Institute of Psychiatry, King's College London, De Crespigny Park, Denmark Hill, London, United Kingdom SE5 8AF

³ Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, IiSGM (CIBERSAM), C/Doctor Esquerdo 46, 28007 Madrid, Spain

⁴ Villa de Vallecas Mental Health Department, Villa de Vallecas Mental Health Centre, Hospital Universitario Infanta Leonor / Hospital Virgen de la Torre, C/San Claudio 154, 28038 Madrid, Spain

⁵ Puente de Vallecas Mental Health Department, Hospital Universitario Infanta Leonor / Hospital Virgen de la Torre, Centro de Salud Mental Puente de Vallecas, C/Peña Gorbea 4, 28018 Madrid, Spain

⁶ Fundación Pública Galega de Medicina Xenómica, Hospital Clínico Universitario, Choupana s/n, 15782 Santiago de Compostela, Spain

- 542 ⁷ Department of Psychiatry, Hospital General Universitario Gregorio Marañón,
543 School of Medicine, Universidad Complutense, IiSGM (CIBERSAM), C/Doctor
544 Esquerdo 46, 28007 Madrid, Spain
- 545 ⁸ Department of Psychiatry, Hospital Clinic, IDIBAPS, Centro de Investigación
546 Biomédica en Red de Salud Mental (CIBERSAM), Universidad de Barcelona,
547 C/Villarroel 170, escalera 9, planta 6, 08036 Barcelona, Spain
- 548 ⁹ Department of Psychiatry, School of Medicine, Universidad de Valencia, Centro de
549 Investigación Biomédica en Red de Salud Mental (CIBERSAM), C/Avda. Blasco
550 Ibáñez 15, 46010 Valencia, Spain
- 551 ¹⁰ Department of Medicine, Psychiatry Area, School of Medicine, Universidad de
552 Oviedo, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM),
553 C/Julián Clavería s/n, 33006 Oviedo, Spain
- 554 ¹¹ Department of Psychiatry, Servicio de Psiquiatría Hospital “Virgen de la Luz”,
555 C/Hermanidad de Donantes de Sangre, 16002 Cuenca, Spain
- 556 ¹² Department of Psychiatry, Early Psychosis Section, Academic Medical Centre,
557 University of Amsterdam, Meibergdreef 5, 1105 AZ Amsterdam, The Netherlands
- 558 ¹³ Rivierduinen Centre for Mental Health, Leiden, Sandifortdreef 19, 2333 ZZ Leiden,
559 The Netherlands
- 560 ¹⁴ Department of Psychiatry and Neuropsychology, School for Mental Health and
561 Neuroscience, South Limburg Mental Health Research and Teaching Network,
562 Maastricht University Medical Centre, P.O. Box 616, 6200 MD Maastricht, The
563 Netherlands
- 564 ¹⁵ AP-HP, Groupe Hospitalier “Mondor”, Pôle de Psychiatrie, 51 Avenue de Maréchal
565 de Lattre de Tassigny, 94010 Créteil, France
- 566 ¹⁶ INSERM, U955, Equipe 15, 51 Avenue de Maréchal de Lattre de Tassigny, 94010
567 Créteil, France
- 568 ¹⁷ Faculté de Médecine, Université Paris-Est, 51 Avenue de Maréchal de Lattre de
569 Tassigny, 94010 Créteil, France
- 570 ¹⁸ Fondation Fondamental, 40 Rue de Mesly, 94000 Créteil, France
- 571 ¹⁹ CMP B CHU, BP 69, 63003 Clermont Ferrand, Cedex 1, France
- 572 ²⁰ EPS Maison Blanche, Paris 75020 France
- 573 ²¹ Université Clermont Auvergne, EA 7280, Clermont-Ferrand, 63000, France
- 574 ²² Department of Experimental Biomedicine and Clinical Neuroscience, Section of
575 Psychiatry, University of Palermo, Via G. La Loggia n.1, 90129 Palermo, Italy

²³ Unit of Psychiatry, “P. Giaccone” General Hospital, Via G. La Loggia n.1, 90129 Palermo, Italy

²⁴ Departamento de Neurociências e Ciências do Comportamento, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Av. Bandeirantes, 3900 - Monte Alegre- CEP 14049-900, Ribeirão Preto, SP, Brasil

²⁵ Núcleo de Pesquisa em Saúde Mental Populacional, Universidade de São Paulo, Avenida Doutor Arnaldo 455, CEP 01246-903, SP, Brasil

²⁶ Section of Psychiatry, Department of Neuroscience, Biomedicine and Movement, University of Verona, Piazzale L.A. Scuro 10, 37134 Verona, Italy

References

1. Marconi A, Di Forti M, Lewis CM, et al. Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis. *Schizophrenia bulletin*. 2016;42:1262-1269.
2. Walter Bromberg. MARIHUANA INTOXICATION. *American Journal of Psychiatry*. 1934;91:303-330.
3. Chopra GS, Smith JW. Psychotic reactions following cannabis use in east indians. *Archives of General Psychiatry*. 1974;30:24-27.
4. Talbott JA, Teague JW. Marihuana psychosis. Acute toxic psychosis associated with the use of Cannabis derivatives. *Jama*. 1969;210:299-302.
5. Spencer DJ. Cannabis-Induced Psychosis. *International Journal of the Addictions*. 1971;6:323-326.
6. Negrete JC, Knapp WP, Douglas DE, et al. Cannabis affects the severity of schizophrenic symptoms: results of a clinical survey. *Psychological medicine*. 1986;16:515-520.
7. Grech A, Van Os J, Jones PB, et al. Cannabis use and outcome of recent onset psychosis. *European psychiatry : the journal of the Association of European Psychiatrists*. 2005;20:349-353.
8. Seddon JL, Birchwood M, Copello A, et al. Cannabis Use Is Associated With Increased Psychotic Symptoms and Poorer Psychosocial Functioning in First-Episode Psychosis: A Report From the UK National EDEN Study. *Schizophrenia bulletin*. 2016;42:619-625.
9. Ringen PA, Nesvag R, Helle S, et al. Premorbid cannabis use is associated with more symptoms and poorer functioning in schizophrenia spectrum disorder. *Psychological medicine*. 2016;46:3127-3136.
10. Addington J, Addington D. Patterns, predictors and impact of substance use in early psychosis: a longitudinal study. *Acta psychiatrica Scandinavica*. 2007;115:304-309.
11. Foti DJ, Kotov R, Guey LT, et al. Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. *The American journal of psychiatry*. 2010;167:987-993.
12. Thornicroft G, Meadows G, Politi P. Is "cannabis psychosis" a distinct category? *European Psychiatry*. 1992;7:277-282.

13. Boydell J, Dean K, Dutta R, et al. A comparison of symptoms and family history in schizophrenia with and without prior cannabis use: implications for the concept of cannabis psychosis. *Schizophr Res.* 2007;93:203-210.
14. van Dijk D, Koeter MW, Hijman R, et al. Effect of cannabis use on the course of schizophrenia in male patients: a prospective cohort study. *Schizophr Res.* 2012;137:50-57.
15. Barrowclough C, Gregg L, Lobban F, et al. The impact of cannabis use on clinical outcomes in recent onset psychosis. *Schizophrenia bulletin.* 2015;41:382-390.
16. Peralta V, Cuesta MJ. Influence of cannabis abuse on schizophrenic psychopathology. *Acta psychiatrica Scandinavica.* 1992;85:127-130.
17. Bersani G, Orlandi V, Kotzalidis GD, et al. Cannabis and schizophrenia: impact on onset, course, psychopathology and outcomes. *Eur Arch Psychiatry Clin Neurosci.* 2002;252:86-92.
18. Zammit S, Moore TH, Lingford-Hughes A, et al. Effects of cannabis use on outcomes of psychotic disorders: systematic review. *The British journal of psychiatry : the journal of mental science.* 2008;193:357-363.
19. Di Forti M, Marconi A, Carra E, et al. Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. *The Lancet Psychiatry.* 2015;2:233-238.
20. Freeman TP, van der Pol P, Kuijpers W, et al. Changes in cannabis potency and first-time admissions to drug treatment: a 16-year study in the Netherlands. *Psychological medicine.* 2018;1-7.
21. ElSohly MA, Mehmedic Z, Foster S, et al. Changes in Cannabis Potency Over the Last 2 Decades (1995-2014): Analysis of Current Data in the United States. *Biological psychiatry.* 2016;79:613-619.
22. Potter DJ, Hammond K, Tuffnell S, et al. Potency of Delta(9) - tetrahydrocannabinol and other cannabinoids in cannabis in England in 2016: Implications for public health and pharmacology. *Drug testing and analysis.* 2018;10:628-635.
23. Quattrone D, Di Forti M, Gayer-Anderson C, et al. Transdiagnostic dimensions of psychopathology at first episode psychosis: findings from the multinational EU-GEI study. *Psychological medicine.* 2018;1-14.
24. Ragazzi TCC, Shuhama R, Menezes PR, et al. Cannabis use as a risk factor for psychotic-like experiences: A systematic review of non-clinical populations evaluated with the Community Assessment of Psychic Experiences. *Early intervention in psychiatry.* 2018;0.
25. Jongsma HE, Gayer-Anderson C, Lasalvia A, et al. Treated Incidence of Psychotic Disorders in the Multinational EU-GEI Study. *JAMA Psychiatry.* 2018;75:36-46.
26. Mallett R. Sociodemographic schedule. Section of Social Psychiatry, Institute of Psychiatry. 1997;183.
27. McGuffin P, Farmer A, Harvey I. A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system. *Archives of general psychiatry.* 1991;48:764-770.
28. Stefanis NC, Hanssen M, Smirnis NK, et al. Evidence that three dimensions of psychosis have a distribution in the general population. *Psychological medicine.* 2002;32:347-358.
29. Di Forti M, Morgan C, Dazzan P, et al. High-potency cannabis and the risk of psychosis. *The British journal of psychiatry : the journal of mental science.* 2009;195:488-491.

30. Quattrone D, Di Forti M, Gayer-Anderson C, et al. Transdiagnostic dimensions of psychopathology at first episode psychosis: findings from the multinational EU-GEI study. *Psychological medicine*. 2018.
31. EMCDDA I: European drug report 2016: trends and developments. European Monitoring Centre for Drugs and Drug Addiction Lisbon; 2013.
32. Di Forti M, Quattrone D, Freeman TP, et al. The Contribution of Cannabis Use to Variation in the Incidence of Psychotic Disorder across Europe: the EUGEI case-control study (accepted for publication). Submitted. 2018.
33. Muthén L, Muthén B: Mplus user's guide (Seventh Edition). Los Angeles, CA, Muthén & Muthén; 2012.
34. Rodriguez A, Reise SP, Haviland MG. Applying Bifactor Statistical Indices in the Evaluation of Psychological Measures. *Journal of personality assessment*. 2016;98:223-237.
35. Hancock GR, Mueller RO: Rethinking construct reliability within latent variable systems. in *Structural Equation Modeling: Present and Future : a Festschrift in Honor of Karl Jöreskog*. Edited by Cudek R, Du Toit S, Sorbom D. Lincolnwood, IL, Scientific Software International, Inc.; 2001. pp. 195-216.
36. Taylor M, Sullivan J, Ring SM, et al. Assessment of rates of recanting and hair testing as a biological measure of drug use in a general population sample of young people. *Addiction*. 2017;112:477-485.
37. Freeman TP, Morgan CJ, Hindocha C, et al. Just say 'know': how do cannabinoid concentrations influence users' estimates of cannabis potency and the amount they roll in joints? *Addiction*. 2014;109:1686-1694.
38. Wolford GL, Rosenberg SD, Drake RE, et al. Evaluation of methods for detecting substance use disorder in persons with severe mental illness. *Psychology of Addictive Behaviors*. 1999;13:313-326.
39. Schubart CD, Sommer IE, van Gastel WA, et al. Cannabis with high cannabidiol content is associated with fewer psychotic experiences. *Schizophr Res*. 2011;130:216-221.
40. McGuire P, Robson P, Cubala WJ, et al. Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial. *The American journal of psychiatry*. 2018;175:225-231.
41. Kendler KS, Gallagher TJ, Abelson JM, et al. Lifetime prevalence, demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a US community sample. The National Comorbidity Survey. *Arch Gen Psychiatry*. 1996;53:1022-1031.
42. Hanssen M, Bak M, Bijl R, et al. The incidence and outcome of subclinical psychotic experiences in the general population. *The British journal of clinical psychology*. 2005;44:181-191.
43. Schoeler T, Petros N, Di Forti M, et al. Effects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis: an observational study. *The Lancet Psychiatry*. 2016;3:947-953.
44. Morrison P, Zois V, McKeown D, et al. The acute effects of synthetic intravenous Δ^9 -tetrahydrocannabinol on psychosis, mood and cognitive functioning. *Psychological medicine*. 2009;39:1607-1616.
45. Murray RM, Englund A, Abi-Dargham A, et al. Cannabis-associated psychosis: Neural substrate and clinical impact. *Neuropharmacology*. 2017;124:89-104.